Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms.
about
Therapeutics development in myotonic dystrophy type 1.The role of CELF proteins in neurological disorders.Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesisCUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.Diverse molecular functions of Hu proteins.A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding.Perspectives on gene therapy in myotonic dystrophy type 1.Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2.CAG repeats mimic CUG repeats in the misregulation of alternative splicing.Altered splicing of Tau in DM1 is different from the foetal splicing process.Dynamic changes of nuclear RNA foci in proliferating DM1 cells.Caenorhabditis elegans Muscleblind homolog mbl-1 functions in neurons to regulate synapse formation.Frontostriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2.Naphthyridine-Benzoazaquinolone: Evaluation of a Tricyclic System for the Binding to (CAG)n Repeat DNA and RNA.Myotonic dystrophy type 1-associated CTG repeats disturb the expression and subcellular distribution of microtubule-associated proteins MAP1A, MAP2, and MAP6/STOP in PC12 cells.Distribution of CTG repeats at the DMPK gene in myotonic dystrophy patients and healthy individuals from the Mexican population.
P2860
Q30425796-EA273981-11D7-409F-98A5-4CF870DE67D5Q34706897-0FA445BE-B239-431B-8547-5E0CB33C735AQ36740042-D2E75240-E6EF-407F-A7D8-013668EBC7EFQ36831893-A5EF7C7B-83E2-49B3-A970-7B5FB835270FQ37200596-0C3094D8-D00D-4529-831E-6932D8E1EC40Q37364023-9890495E-69EA-4EF0-A4D9-667B69046AB6Q37831858-954FD2B4-CC79-48B5-B5CD-663F25ECA38FQ38789617-8FA31620-7DF1-4773-877E-221BA1153B29Q38855978-9F873658-41CA-4425-AD24-7C00303139A2Q39891392-467F9FF3-8471-40B0-818F-CC18212ED554Q40902020-0BA2F37F-7913-4274-B8A4-2D214F5B7E56Q42045833-AAAC4238-EE5F-4916-B5E8-FB3CA238F893Q48474798-E2447530-1698-484A-8C33-56DF58AAAB3FQ51345171-31E1635A-E4D9-46ED-92AF-E1AF6ECDCBA4Q54373351-34E822D8-30B0-43A8-8488-5206AE56A0F2Q54419540-D15D525A-A7A5-454F-A3DD-4EFC69F149AB
P2860
Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms.
@en
type
label
Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms.
@en
prefLabel
Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms.
@en
P2860
P356
P1476
Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms.
@en
P2093
Bulmaro Cisneros
Mario Bermúdez de León
P2860
P356
10.1002/JNR.21377
P577
2008-01-01T00:00:00Z